Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 ...

After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer ...